You searched for heart - Page 2 of 32

Japan conditionally approves new IPS cell-based heart study

May 20, 2018 December 22, 2023 / By Professor Paul Knoepfler, Ph.D. / 5 Comments

Yoshiki-Sawa-IPS-cells-stem-cells-heart-diseease

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work …

Japan conditionally approves new IPS cell-based heart study Read More »

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

July 9, 2017 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 4 Comments

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse …

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »

Statins dilemma: heart & cancer benefits, but diabetes risk

May 12, 2015 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 7 Comments

Statins have been hailed as some of the best drugs ever. Given the massive, deadly prevalence of cardiovascular disease, some have even semi-jokingly talked about putting these drugs in the water supply for public health. The growing evidence (e.g. this story) that statins might significantly aid in prevention, delayed progression, or even post-treatment delay of …

Statins dilemma: heart & cancer benefits, but diabetes risk Read More »

Bioheart on the edge in 2015?

May 6, 2015 February 1, 2021 / By Professor Paul Knoepfler, Ph.D.

Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy …

Bioheart on the edge in 2015? Read More »

Interview with Bioheart CSO, Kristin Comella including on FDA

April 21, 2015 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 13 Comments

I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem …

Interview with Bioheart CSO, Kristin Comella including on FDA Read More »

Can hearts fix themselves via stem cells?

January 6, 2015 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 5 Comments

Can hearts repair themselves via stem cell mechanisms including possibly their own stem cells? It’s a hot topic question at the center of a big debate in the stem cell field. My inclination at present is that the answer is most likely “no” at this point, but that could change and it’s important to keep …

Can hearts fix themselves via stem cells? Read More »

Transdifferentiation meets gene therapy to tackle heart disease

April 19, 2012 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 1 Comment

The leading cause of death in America and many other countries of the world is cardiovascular disease (CVD) including heart attacks and strokes. In fact, CVD kills and disables more people than most often top killers combined including cancer. The myth that CVD is a “man’s disease” only makes the situation worse as in reality CVD …

Transdifferentiation meets gene therapy to tackle heart disease Read More »

Weekly reads: abundant Abcam prices, speedy aging & cancer, stemmy CAR-T, more on STAP

April 14, 2024 April 13, 2024 / By Professor Paul Knoepfler, Ph.D. / 3 Comments

When a vendor of important reagents like antibody supplier Abcam charges big money, those high Abcam prices could negatively impact research in the long run. Some of the prices are so high that buying just a few antibodies could take up a small but meaningful slice of an entire R01 grant. Sky-high Abcam prices I’ve …

Weekly reads: abundant Abcam prices, speedy aging & cancer, stemmy CAR-T, more on STAP Read More »

Key Mayo Clinic stem cell webpage is overexuberant & outdated

March 21, 2024 March 30, 2024 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

The Mayo Clinic does some great research on stem cells and regenerative medicine. However, at times I’ve felt that a few Mayo researchers are overexuberant. This mainly relates to certain not-yet-proven stem cell and related offerings. Fitting with that perception, the Mayo website also has some inaccurate stem cell content that leans toward overstating things. …

Key Mayo Clinic stem cell webpage is overexuberant & outdated Read More »

Weekly reads: elephant stem cells, RIP Connie Eaves, AI cell biology

March 17, 2024 March 16, 2024 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

Last week one of the most popular stories was about a preprint from a mammoth de-extinction research group led by George Church having made elephant stem cells. I finally got a chance to look carefully at their preprint. Elephant stem cells preprint and mammoth de-extinction The elephant stem cells preprint has solid data. It looks like …

Weekly reads: elephant stem cells, RIP Connie Eaves, AI cell biology Read More »

Search Results for: heart